Nesher Pharmaceutical gets final approval for Dextroamphetamine Sulfate ER Capsules

From USFDA

Nesher Pharmaceutical, a subsidiary of Zydus Pharmaceutical USA has received final approval from USFDA to market Dextroamphetamine Sulfate Extended-Release Capsules, 5 mg.

The drug will be produced at the Nesher Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA.

Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyperactive Disorder (ADHD) and in the treatment of narcolepsy (a special type of sleep disorder).

Powered by Capital Market - Live News